Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris

Strasbourg, France, November 25, 2025, 7:45 p.m. CET – Transgene (Euronext Paris: TNG) has requested Euronext Paris to suspend trading of its shares (ISIN: FR0005175080) as of Wednesday, November 26, 2025, before the markets open, pending the publication of the results of its capital increase.

Trading on Euronext Paris is expected to resume on Thursday, November 27, 2025, at the opening of the markets.

***

Contacts

About Transgene 

Transgene (Euronext: TNG) is a biotechnology company that designs and develops immunotherapy products for cancer treatment. Transgene’s portfolio consists of several viral vector-based immunotherapies in clinical development. TG4050, the Company’s lead candidate, is the first individualized treatment from the myvac® platform and has demonstrated clinical proof of concept in patients with head and neck cancer treated in an adjuvant setting. The company is developing other viral vector-based candidates such as BT-001, an oncolytic virus based on the patented virus of the invir.IO® platform, which is in clinical development. The company is conducting other research programs based on its viral vector technology to support the development of its portfolio of candidates.
With myvac®, therapeutic vaccination enters the field of precision medicine with innovative, patient-specific immunotherapy. This immunotherapy makes it possible to integrate tumor mutations identified and selected using artificial intelligence provided by its partner NEC into a viral vector.
Invir.IO®, a platform developed from Transgene’s expertise in viral vector engineering, enables the design of a new generation of multifunctional oncolytic viruses.
For more information, visit www.transgene.com.
Follow us on X (formerly Twitter): @TransgeneSA, LinkedIn: @Transgene, and Bluesky: @Transgene
Transgene forward-looking statements

This press release contains forward-looking statements and/or information that may be subject to a number of risks and uncertainties, such that actual results may differ materially from those anticipated. There can be no assurance (i) that the results of preclinical studies and previous clinical trials will be predictive of the results of the clinical trials currently underway, (ii) that regulatory approvals for Transgene’s therapies will be obtained, or (iii) that the Company will find partners to develop and commercialize its therapies within a reasonable timeframe and on satisfactory terms. The occurrence of these risks could have a material adverse effect on the Company’s business, prospects, financial condition, results, or developments. For a description of the risks and uncertainties that could affect the Company’s results, financial condition, performance, or achievements and thus cause a deviation from the forward-looking statements, please refer to the section “Risk Factors” ” section of the Universal Registration Document filed with the AMF, available on the AMF website (www.amf-france.org) and the Company’s website ( (www.transgene.com)), and in the 2025 half-year financial report available on the Company’s website (www.transgene.com). Forward-looking statements are valid only as of the date of this document, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Disclaimer

This press release does not constitute an offer to sell or the solicitation of an offer to purchase any of the Company’s common shares, and may not be issued or distributed in any jurisdiction where such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
The distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release should inform themselves of and comply with such restrictions.
This press release is an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 (as amended, the “Prospectus Regulation“). Any decision to purchase shares should be made solely on the basis of publicly available information about the Company.

France
In France, the offering of Transgene shares described below will be carried out as part of (i) a capital increase reserved for specific categories of beneficiaries, in accordance with Article L. 225-138 of the French Commercial Code and applicable regulatory provisions, (ii) a public offering, mainly intended for individuals via the PrimaryBid platform, in accordance with Article L. 225-136 of the French Commercial Code.

European Economic Area
With regard to the Member States of the European Economic Area, no action has been taken and will be taken to allow a public offering of the shares referred to in this press release that would require the publication of a prospectus in any of the Member States. Consequently, the shares may not be offered and will not be offered in any of the Member States, except in accordance with the exemptions provided for in Article 1(4) of the Prospectus Regulation or in other cases where the Company is not required to publish a prospectus under Article 3 of the Prospectus Regulation and/or the regulations applicable in that Member State.

United Kingdom
This press release and the information contained herein are intended solely for persons located (x) outside the United Kingdom or (y) in the United Kingdom who are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order“), (ii) “high net worth entities” and other persons falling within Article 49(2)(a) to (d) of the Order (“high net worth companies, unincorporated associations, etc.” ) or (iii) persons to whom an invitation or inducement to participate in an investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) may be lawfully communicated or transmitted (the persons referred to in paragraphs (y)(i), (y)(ii) and (y)(iii) being collectively referred to as “Eligible Persons“). Any invitation, offer or agreement to subscribe for or purchase financial securities referred to in this press release is only available to Eligible Persons. Any person who is not an Eligible Person should not act or rely on this press release or its contents.

United States of America
This press release may not be distributed, directly or indirectly, in the United States. This press release and the information contained herein do not constitute an offer to subscribe or purchase, or a solicitation of an order to purchase or subscribe for, securities in the United States or in any other jurisdiction in which the transaction may be subject to restrictions. Securities may not be offered or sold in the United States without registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act“). Transgene’s securities have not been and will not be registered under the U.S. Securities Act, and the Company does not intend to make a public offering in the United States.

MiFID
MIFID II Product governance/target market: for the sole purposes of the requirements of Article 9.8 of Delegated Directive (EU) 2017/593 on the product approval process, the assessment of the target market for Transgene shares has led to the conclusion, with regard to the type of clients criterion only, that: (i) the type of clients for whom the shares are intended is eligible counterparties and professional clients [and retail clients], each as defined in Directive 2014/65/EU, as amended (“MiFID II“); and (ii) all distribution channels for Transgene shares to eligible counterparties and professional clients [and retail clients] are appropriate. Any person subsequently offering, selling or recommending Transgene shares (a “distributor“) should take into consideration the assessment of the type of clients; however, a distributor subject to MiFID II is responsible for conducting its own assessment of the target market with respect to Transgene shares and determining the appropriate distribution channels.

General
The distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release should inform themselves of and comply with any such restrictions.
Any decision to subscribe for or purchase shares or other securities of Transgene should be made solely on the basis of publicly available information about Transgene. This information is not the responsibility of Van Lanschot Kempen NV or Swiss Life Private Bank and has not been independently verified by Kempen or Swiss Life Private Bank.

Attachment

• 20251125_PR_Suspension-Trading_TNG_EN